Abstract: The present application provides an organic light emitting diode (OLED) display panel and a method of manufacturing the same, and a display terminal. The OLED display panel includes an array substrate, a protective layer and a cathode. The array substrate includes a first auxiliary electrode, a second auxiliary electrode, and a third auxiliary electrode. The third auxiliary electrode is connected to the first auxiliary electrode and the second auxiliary electrode. The protective layer is provided with an undercut opening exposing a portion of the third auxiliary electrode. The cathode extends into the undercut opening and is connected to the third auxiliary electrode.

Abstract: An array substrate and a display panel. The array substrate provided in the embodiments of the present application includes: a base including a flat portion and a recess portion so that the base includes a concave hole corresponding to the bending area; a semiconductor component layer provided on the base and including a plurality of interlayer insulation layers and a plurality of metal layers, the interlayer insulation layers being not aligned horizontally in the peripheral area and the wire switching area to form a stepped hole including a first hole and a second hole, wherein a third metal layer of the metal layers extends along a sidewall and a bottom of the stepped hole and is electrically connected to a first metal layer of the metal layers.

Abstract: Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate protein, wherein said immunoconjugate protein comprises a hybrid Fc region of an IgG1 and an IgG3 immunoglobulin conjugated to Factor VII. These immunoconjugates can target Tissue Factor (TF) expressing cells.

Abstract: The present invention relates to a ventilating and blanking device for a coal storage Eurosilo. The ventilating and blanking device includes a top blanking pipe, an axial flow fan and a baffle door, the top blanking pipe including a first pipeline and a second pipeline, an air supply pipe is connected to a side wall of the second pipeline, and the baffle door is connected to a driving mechanism; during blanking, the driving mechanism drives the baffle door so as to make the baffle door close the air supply pipe and the axial flow fan is shut off; and during ventilation, the driving mechanism drives the baffle door so as to make the baffle door close the first pipeline, and the axial flow fan is turned on. Compared with the prior art, the present invention has the advantages of ventilation efficiency, good ventilation effect, etc.

Abstract: Provided in the embodiments of the present application is a blockchain hybrid consensus-based system for maintaining domain name information. A gTLD blockchain is formed by first network nodes where international generic top-level domain registries are located, and a ccTLD blockchain is formed by second network nodes where various countries codes top-level domain registries are located. In each blockchain, various network nodes of the blockchain participate in the domain name information update process, so that the domain name information update process will not be affected by a mistake or an attack on one network node. Compared to centralized maintenance methods, this decentralized maintenance method is more secure and is beneficial to maintaining the stability of the system.

Abstract: Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate protein, wherein said immunoconjugate protein comprises a hybrid Fc region of an IgG1 and an IgG3 immunoglobulin conjugated to Factor VII. These immunoconjugates can target Tissue Factor (TF) expressing cells.

Abstract: A system is provided for detecting the mass of oil in an inorganic mineral of shale. The system operates by performing an extraction test on a first shale sample by using chloroform to obtain a total content of shale oil in the shale; enriching kerogen from the second shale sample to obtain dry kerogen; and performing an extraction test on oven-dried kerogen by using chloroform to determine the mass of extracted kerogen. The system also operates by determining the mass of the oil in the organic matter of the shale sample and the mass of the oil in an inorganic mineral of the shale; establishing a model for predicting a ratio of the mass of the oil in the inorganic mineral of the shale to the mass of the oil in the organic matter; and using the prediction model to determine the mass of oil in an inorganic mineral.

Abstract: A method for identifying mineral pore types in mud shale includes: determining an inorganic mineral pore image and a kerogen region image of a mud shale Scanning Electron Microscopy (SEM) gray-scale image; performing an expansion operation on the inorganic mineral pore image to obtain an expanded inorganic mineral pore image; comparing the inorganic mineral pore image with the expanded inorganic mineral pore image, and determining an extra region in the expanded inorganic mineral pore image as an expansion region; collecting statistics about the number of pixel points of a siliceous mineral, a calcareous mineral, and a clay mineral; calculating the proportion of each mineral according to the number of pixel points of the minerals; drawing a mineral pore triangular image chart according to the proportions of minerals; and determining the mineral type corresponding to the pores in the inorganic mineral pore image according to the mineral pore triangular image chart.

Abstract: The present disclosure provides a lens structure and a photographic device. The lens structure includes a lens barrel, a ball assembly, and a sleeve. The ball assembly is disposed on an outer surface of the lens barrel. The sleeve receives the lens barrel and the ball assembly. The sleeve is in rolling contact with the lens barrel via the ball assembly.

Abstract: A system is provided for detecting the mass of oil in an inorganic mineral of shale. The system operates by performing an extraction test on a first shale sample by using chloroform to obtain a total content of shale oil in the shale; enriching kerogen from the second shale sample to obtain dry kerogen; and performing an extraction test on oven-dried kerogen by using chloroform to determine the mass of extracted kerogen. The system also operates by determining the mass of the oil in the organic matter of the shale sample and the mass of the oil in an inorganic mineral of the shale; establishing a model for predicting a ratio of the mass of the oil in the inorganic mineral of the shale to the mass of the oil in the organic matter; and using the prediction model to determine the mass of oil in an inorganic mineral.

Abstract: A method for identifying mineral pore types in mud shale includes: determining an inorganic mineral pore image and a kerogen region image of a mud shale Scanning Electron Microscopy (SEM) grayscale image; performing an expansion operation on the inorganic mineral pore image to obtain an expanded inorganic mineral pore image; comparing the inorganic mineral pore image with the expanded inorganic mineral pore image, and determining an extra region in the expanded inorganic mineral pore image as an expansion region; collecting statistics about the number of pixel points of a siliceous mineral, a calcareous mineral, and a clay mineral; calculating the proportion of each mineral according to the number of pixel points of the minerals; drawing a mineral pore triangular image chart according to the proportions of minerals; and determining the mineral type corresponding to the pores in the inorganic mineral pore image according to the mineral pore triangular image chart.

Abstract: Disclosed are methods and compositions related to chimeric antigen receptors (CARs) that recognize Tissue Factor (TF). Specifically, disclosed are CARs that comprise fVII or a functional fragment thereof. Also disclosed are immune effector cells comprising the CARs disclosed herein.

Abstract: Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate protein, wherein said immunoconjugate protein comprises a hybrid Fc region of an IgG1 and an IgG3 immunoglobulin conjugated to Factor VII. These immunoconjugates can target Tissue Factor (TF) expressing cells.

Abstract: The invention discloses a user information pushing method, a user information representation method, a system, a server and a client. The pushing method includes: arranging a plurality of service interfaces to be invoked by the client, wherein the service interfaces comprise a real-time information pushing interface; receiving, by a server, through the real-time information pushing interface, a real-time information acquisition instruction sent by the client, when the client uses a target service and automatically invokes the real-time information pushing interface; acquiring real-time information of the target service according to a subscriber number contained in the real-time information acquisition instruction; and pushing the real-time information to the client.

Abstract: Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

Abstract: The present invention provides a macroporous microcarrier specific to hepatocytes using silk fibroin and galactosylated chitosan as main raw material, a preparation method thereof, and application for hepatocyte culture under the culture condition of microgravity rotation. The macroporous microcarrier s a sphere prepared from silk fibroin and galactosylated chitosan under the effect of crosslinker, wherein based on the total weight of the sphere, the content of silk fibroin is 50-80 wt % and the content of galactosylated chitosan is 15-40 wt %. The diameter of the microcarrier is 200-500 ?m, and the aperture of the microcarrier is 40-80 ?m.

Abstract: Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

Abstract: Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

Abstract: Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

Abstract: Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.